HTLV-1 Envelope, Human T-Lymphocyte Virus Antigen, Recombinant

Full Name

Abbreviated Name-1

rHTLV-I; HTLVI envelope; HTLV-1 envelope; HTLV1 envelope

Documents
Figures
Reference
Eshima N, Tabata M et al. Population dynamics of HTLV-I infection: a discrete-time mathematical epidemic model approach. Math Med Biol. Mar 2003;20(1):29-45. Furukawa Y, Kubota R et al. Existence of escape mutant in HTLV-I tax during the development of adult T-cell leukemia. Blood. Feb 2001;97(4):987-93. Nath MD, Ruscetti FW et al. Regulation of the cell-surface expression of an HTLV-I binding protein in human T cells during immune activation. Blood. Apr 2003;101(8):3085-92.

Description

GenScript Human T-Lymphocyte Virus (HTLV)-1 Envelope contains the C- terminus of gp46 and most of p21E of HTLV-I. This non-fusion, E. coli-derived protein starts from HIV-1 env. amino acid 165, and ends in amino acid 440. Human T-cell Leukaemia Virus Type I (HTLV-I) is a retrovirus that causes adult T-cell leukaemia (ATL).

Source

E. coli

Purity

Protein is >95% pure (as determined by HPLC-C4, and 10% PAGE).

Storage

Store at -20°C. Keep container tightly closed.

Concentration

1 mg/ml in 10 mM Na-PO₄, pH 6.0, containing 0.1% SDS, and 1 mM DTT; final concentration: 1 mg per vial

Stability

The protein will remain stable for five years if stored frozen and for six months in solution if stored in solution at 4°C.

Specificity

This protein is immunoreactive with all sera of HTLV-I and HTLV-II infected individuals with antibody response to HTLV envelope.

Applications

Use this protein as an antigen in ELISA and western Blots. It makes an excellent reagent in the correct detection of HTLV infections. It shows minimal specificity problems.

Note

;

Related Products

Cat. No.	Name	Size	Price
RP17316	HIV p17 Gag (77-85)	1 mg	$99
Z00150	HIV-1 p24 Core, Human Immunodeficiency Virus Antigen, Recombinant	1 mg	$1000


1	Custom Recombinant Protein Services: Guaranteed E. coli Expression Package-3 mg purified soluble protein from $2,200 .
2	Bacterial Expression System: GenScript has developed BacPower^TM technologies to tackle hard-to-express and hard-to-dissolve proteins.
3	Yeast Expression System: GenScript's proprietary YeastHIGH^TM technology combines the advantages of the bacterial and eukaryotic expression systems.
4	Baculovirus/Insect Cell Expression System: GenScript developed BacuVance^TM platform for the secretion of recombinant proteins from baculovirus-infected insect cells.
5	Mammalian Cell Expression System: The proprietary 293 and CHO suspension system platform promotes fast production and delivery of recombinant proteins and monoclonal antibodies up to grams level.